Oncotelic Therapeutics Inc.’s (OTLC) Sapu003: Injectable Everolimus (Afinitor(R)) to Begin Clinical Trials, Aiming to Boost Drug Bioavailability
- Oncotelic Therapeutics developed the Deciparticles(TM) technology to improve the bioavailability of drugs, largely thanks to the creation of sub-20nm size of the nanoparticles
- Sapu Nano, part of Oncotelic’s GMP Bio joint venture, receives clearance to begin Phase 1 trial of Sapu003, an injectable form of Everolimus (Afinitor(R)) for breast cancer
- In preclinical studies, Sapu003 could raise the bioavailability of Everolimus (Afinitor(R)) from around 10%, as oral pill, up to anywhere from 80 to 100%, as injectable
- Result hopes for higher bioavailability in that drugs may have dramatically better, faster, and more consistent efficacy for patients
Oncotelic Therapeutics (OTCQB: OTLC) is a clinical-stage biopharmaceutical company advancing a diversified pipeline spanning oncology, immunotherapy, neurodegeneration, and rare diseases. In a recent interview on the BioMedWire podcast, Chairman and CEO Dr. Vuong Trieu emphasized the company’s unique model: focusing on de-risked, late-stage assets and accelerating their development through regulatory pathways designed for speed and efficiency.
The technology, called Deciparticles(TM), is being developed by Sapu Nano, a member of the Sapu family of companies, which is established through GMP Biotechnology Limited, which itself is a joint venture between Oncotelic Therapeutics and Dragon Overseas Capital Limited. This technology enabled creation of sub-20 nm nanoparticles that aim to overcome common drug-related problems like subpar bioavailability and limited penetration, by utilizing tiny particles to enhance the delivery.
The concept lies within the incredibly small size of Deciparticles(TM), meaning that more of the drug may be able to quickly exit the blood vessels and reach the tumor more effectively vs. drugs that use larger particles.
For patients, this could mean that drugs work faster, more consistently, and are stronger. In terms of impact, this could mean anything from slowing down cancer growth, to even eliminating it in some cases. The technology is also scalable and could offer wide-ranging benefits for various types of drugs. Oncotelic is hopeful of robust outcomes in the clinical trials ahead.
Dr. Trieu also went into more detail about Deciparticles(TM), saying that the technology and pipeline was created at the company’s GMP-certified manufacturing facility in San Diego, CA. The facility was built from the ground up by the team and is the first one in the world to be developing Deciparticles(TM).
About Oncotelic Therapeutics
Oncotelic Therapeutics is a biopharmaceutical company that develops treatments for cancer and other diseases. It has a collection of both preclinical and clinical-stage candidates that are focused primarily on areas that have a significant unmet need.
For more information, visit the company’s website at www.Oncotelic.com.
NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://nnw.fm/OTLC
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
- Oncotelic Therapeutics developed the Deciparticles(TM) technology to improve the bioavailability of drugs, largely thanks to the creation of sub-20nm size of the nanoparticles
- Sapu Nano, part of Oncotelic’s GMP Bio joint venture, receives clearance to begin Phase 1 trial of Sapu003, an injectable form of Everolimus (Afinitor(R)) for breast cancer
- In preclinical studies, Sapu003 could raise the bioavailability of Everolimus (Afinitor(R)) from around 10%, as oral pill, up to anywhere from 80 to 100%, as injectable
- Result hopes for higher bioavailability in that drugs may have dramatically better, faster, and more consistent efficacy for patients
Oncotelic Therapeutics (OTCQB: OTLC) is a clinical-stage biopharmaceutical company advancing a diversified pipeline spanning oncology, immunotherapy, neurodegeneration, and rare diseases. In a recent interview on the BioMedWire podcast, Chairman and CEO Dr. Vuong Trieu emphasized the company’s unique model: focusing on de-risked, late-stage assets and accelerating their development through regulatory pathways designed for speed and efficiency.
The technology, called Deciparticles(TM), is being developed by Sapu Nano, a member of the Sapu family of companies, which is established through GMP Biotechnology Limited, which itself is a joint venture between Oncotelic Therapeutics and Dragon Overseas Capital Limited. This technology enabled creation of sub-20 nm nanoparticles that aim to overcome common drug-related problems like subpar bioavailability and limited penetration, by utilizing tiny particles to enhance the delivery.
The concept lies within the incredibly small size of Deciparticles(TM), meaning that more of the drug may be able to quickly exit the blood vessels and reach the tumor more effectively vs. drugs that use larger particles.
For patients, this could mean that drugs work faster, more consistently, and are stronger. In terms of impact, this could mean anything from slowing down cancer growth, to even eliminating it in some cases. The technology is also scalable and could offer wide-ranging benefits for various types of drugs. Oncotelic is hopeful of robust outcomes in the clinical trials ahead.
Dr. Trieu also went into more detail about Deciparticles(TM), saying that the technology and pipeline was created at the company’s GMP-certified manufacturing facility in San Diego, CA. The facility was built from the ground up by the team and is the first one in the world to be developing Deciparticles(TM).
About Oncotelic Therapeutics
Oncotelic Therapeutics is a biopharmaceutical company that develops treatments for cancer and other diseases. It has a collection of both preclinical and clinical-stage candidates that are focused primarily on areas that have a significant unmet need.
For more information, visit the company’s website at www.Oncotelic.com.
NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://nnw.fm/OTLC
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
